Immatics N.V. (IMTX) 株式分析

企業概要

Immatics N.V. is a clinical-stage biopharmaceutical enterprise dedicated to the research and development of potential T cell redirecting immunotherapies for cancer treatment within the United States. The company operates within the healthcare sector and specifically targets the biotechnology industry, where it pursues the creation of targeted immunotherapies with a focus on treating solid tumors. As of the latest data, the enterprise possesses a market capitalization of $1.43 billion, reports annual revenue of $48.27 million over the trailing twelve months, and maintains an employee base of 589 individuals. The market capitalization of $1.43 billion combined with the revenue figure of $48.27 million indicates that the company holds a significant valuation relative to its current top-line generation, a characteristic often observed in capital-intensive biotechnology firms at the clinical stage where substantial investment is required prior to commercialization. This scale, supported by a workforce of 589 employees, reflects the extensive resources necessary for advancing complex immunotherapy platforms through clinical trials toward potential market approval.

財務健全性

The company reported a revenue of $48.27 million for the trailing twelve months, yet recorded a net income of $-196,447,008 and an EBITDA of $-172,875,008. The substantial gap between the positive revenue of $48.27 million and the negative net income of $-196,447,008 reveals a highly leveraged cost structure where operating expenses, likely driven by research and development activities and general administrative costs, significantly exceed total sales. Furthermore, the company generated a free cash flow of $-128,190,248, which indicates a negative cash position that implies limited financial flexibility and a heavy reliance on external capital sources such as equity financing or debt issuance to fund ongoing operations. Analysis of the margin structure shows a gross margin of -280.9%, an operating margin of -196.8%, and a profit margin of 0.0%, all of which indicate that the company is currently incurring losses on nearly all units sold or that costs are not yet covered by revenue, a typical scenario for pre-commercial biotechnology entities. Regarding liquidity and leverage, the company holds cash of $469.34 million against a debt load of $15.63 million, resulting in a debt-to-equity ratio of 3.23. Despite the high debt-to-equity ratio of 3.23, the balance sheet appears to be less conservative in terms of leverage due to the massive cash reserve, though the negative equity implied by the debt-to-equity metric suggests a high risk profile. The current ratio stands at 11.72, which indicates an extremely strong short-term liquidity position where current assets far exceed current liabilities, providing ample buffer for operational needs. Additionally, the return on equity is -37.1% and the return on assets is -18.1%, revealing that management effectiveness is currently measured by the ability to navigate negative returns while preserving capital for future clinical milestones rather than generating immediate shareholder value.

バリュエーション評価

The valuation metrics for Immatics N.V. show a P/E Ratio (TTM) of N/A and a forward P/E of -6.04. The absence of a trailing P/E and the negative forward P/E of -6.04 imply that the company is not yet profitable and that future earnings estimates are currently negative, reflecting the early-stage nature of its clinical development pipeline. The price-to-book ratio is recorded at 2.55, which indicates that the market values the company at a premium of 2.55 times its book value, suggesting investor confidence in the intangible assets and future potential of the biotechnology platform despite current losses. Alternative valuation metrics include a price-to-sales ratio of 29.62 and an EV/EBITDA of -5.64, which suggest that the market is pricing the stock based on revenue multiple expansion rather than earnings power, a standard practice for clinical-stage companies where revenue is the primary proxy for progress. The stock has traded within a 52-week high of $12.41 and a 52-week low of $3.45. Without a specific current price provided in the available facts to calculate a precise percentage, the trading range demonstrates significant volatility, with the security capable of moving between the high of $12.41 and the low of $3.45. The beta value is 1.34, which means the stock exhibits price volatility that is 34% higher than the broader market, indicating that the asset is more sensitive to market fluctuations than the average equity in the S&P 500 index.

Growth & Income

The revenue growth year-over-year is -64.9%, while the earnings growth year-over-year is N/A. The contraction in revenue of 64.9% combined with the unavailable earnings growth data implies that the company is in a phase of strategic transition or market adjustment where top-line generation is declining, and without profitable operations, earnings cannot grow. As a non-dividend payer, the company does not distribute a dividend yield, which has a payout ratio of 0.0%. The zero payout ratio confirms that the company reinvests all available resources, including its substantial cash reserves, back into research, development, and clinical trials rather than distributing income to shareholders. This growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting the capital-intensive and high-risk nature of clinical-stage biotechnology where capital preservation for clinical milestones takes precedence over shareholder distributions. The overall profile suggests a high-risk, high-potential asset that relies on successful clinical outcomes to reverse the negative revenue trend and eventually achieve profitability.